drugset / Trial / NCT03146663
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer. The primary objective was to determine the anti-tumor activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
Timeline
- Start
- 2017-09-28
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FOSGEMCITABINE PALABENAMIDE | Small molecule | 500 mg/m2 | Intravenous |
| Subject | FOSGEMCITABINE PALABENAMIDE | Small molecule | 750 mg/m2 | Intravenous |